S&P Futures
3,833.50+5.50(+0.14%)Dow Futures
31,399.00+28.00(+0.09%)Nasdaq Futures
12,803.50-28.25(-0.22%)
Novo Nordisk A/S (NVO)
72.98 +0.64 (0.88%)
After hours: 7:59PM EST
Chart Events
Performance Outlook
| Previous Close | 72.19 |
| Open | 72.76 |
| Bid | 72.25 x 900 |
| Ask | 73.00 x 1100 |
| Day's Range | 72.19 - 73.00 |
| 52 Week Range | 49.24 - 75.86 |
| Volume | 1,070,271 |
| Avg. Volume | 1,082,208 |
| Market Cap | 166.946B |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | 29.38 |
| EPS (TTM) | 2.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.90 (2.63%) |
| Ex-Dividend Date | Mar 26, 2021 |
| 1y Target Est | 81.16 |
Fair Value
Related Research
- Insider Monkey
Top 15 Pharmaceutical Companies With Highest R&D Spending
In this article we are going to list the top 15 pharmaceutical companies with the highest R&D spending. Click to skip ahead and jump to the Top 5 Pharmaceutical Companies With Highest R&D Spending. Pharma companies have always been among the most important companies in the world, even if they have been much maligned as […]
- GlobeNewswire
Notice for the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 23 February 2021 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 25 March 2021 at 14:00 (CET) Due to COVID-19, the Annual General Meeting is held as a fully virtual meeting and shareholders will not be able to be physically present at the meeting. Instead, shareholders will be able to participate via an IT application and we encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk’s website. Please refer to the notice for further information. The notice for the Annual General Meeting, including Appendix: Candidates for the Board of Directors, is enclosed. BOARD OF DIRECTORS All board members elected by the Annual General Meeting are up for election. Brian Daniels and Liz Hewitt have decided not to seek re-election. The Board of Directors proposes re-election of the following board members elected by the Annual General Meeting: Helge Lund (chair), Jeppe Christiansen (vice-chair), Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim Kutay and Martin Mackay. The Board of Directors proposes the election of Henrik Poulsen as a new member of the Board. Mr Poulsen served as CEO and president of the renewable energy company Ørsted A/S, Denmark, in the period 2012-2020. Prior to that Mr Poulsen was CEO and president of the telecommunication company TDC A/S, Denmark. From 2007-2008 Mr Poulsen served as operating executive of Kohlberg Kravis Roberts & Co. in the UK preceded by executive roles with the LEGO group, Denmark, in the period 1999-2006. The Board of Directors proposes the election of Henrik Poulsen to the Board of Directors primarily because of his extensive executive and board experience in large international companies, significant financial knowledge and in-depth knowledge of strategy, transformation, innovation, and mergers and acquisitions. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Media: Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.comMichael Bachner (US)+1 609 664 7308mzyb@novonordisk.com Investors: Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.comValdemar Borum Svarrer+45 3079 0301jvls@novonordisk.comAnn Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.comMark Joseph Root+45 3079 4211mjhr@novonordisk.comKristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement No 15 / 2021 Attachment CA210223_AGM_Notice_combined
- GlobeNewswire
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 22 February 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme initiated 3 February 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 3 February 2021 to 3 May 2021. Since the announcement as of 15 February 2021, the following transactions have been made: Number ofB sharesAveragepurchase priceTransactionvalue, DKKAccumulated, last announcement848,375 377,636,38315 February 2021115,000462.3653,170,84516 February 2021115,000459.6052,854,02917 February 2021115,000460.9253,005,63218 February 2021110,000461.4050,754,36019 February 2021115,000455.5852,391,244Accumulated under the programme1,418,375 639,812,494 The details for each transaction made under the share repurchase programme are published on novonordisk.com. With the transactions stated above, Novo Nordisk owns a total of 40,331,566 B shares of DKK 0.20 as treasury shares, corresponding to 1.7% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares. Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 3 February 2021. As of 19 February 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 1,418,375 B shares at an average share price of DKK 451.09 per B share equal to a transaction value of DKK 639,812,494. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Media: Anne Margrethe Hauge+45 3079 3450amhg@novonordisk.comMichael Bachner (US)+1 609 664 7308mzyb@novonordisk.com Investors: Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.comValdemar Borum Svarrer+45 3079 0301jvls@novonordisk.comAnn Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.comMark Joseph Root+45 3079 4211mjhr@novonordisk.comKristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement no. 14 / 2021 Attachment CA_210222_SafeHarbour
